logo
NeuralBase Provides Update on BMP AI Platform Development and Targeted Q4 2025 Feature Releases

NeuralBase Provides Update on BMP AI Platform Development and Targeted Q4 2025 Feature Releases

LAS VEGAS, NV - July 8, 2025 ( NEWMEDIAWIRE ) - Neuralbase AI Ltd. (OTC: NBBI), operating under its enterprise brand BMP AI and a growing innovator in enterprise artificial intelligence, today provided a product development update outlining recent progress on its BMP AI platform and key features targeted for release in Q4 2025.
The BMP AI platform is Neuralbase AI's proprietary document-grounded enterprise AI system designed for deployment across highly regulated industries, including healthcare, financial services, legal services, government, and enterprise knowledge management sectors. BMP AI leverages retrieval-augmented generation (RAG), vector search, explainability tooling, and enterprise-grade governance features to deliver secure, compliant AI assistants capable of automating document workflows while preserving auditability and regulatory oversight.
The Company is actively advancing development of several new platform modules, including:
'We are building BMP AI not simply as an AI engine, but as a fully governed enterprise platform designed from the ground up to address the unique challenges facing regulated organizations adopting AI,' said Vighnesh Dobale, Chief Executive Officer of Neuralbase AI Ltd. 'These targeted feature releases reflect our continued execution toward scalable enterprise deployment while maintaining our core focus on compliance, explainability, and document-grounded intelligence.'
The Company expects to begin phased availability of these features in Q4 2025 as part of its ongoing product development roadmap. Neuralbase AI is also continuing to engage in global AI industry forums as part of its broader market development program, including participation in the upcoming Global AI Show Abu Dhabi in December 2025.
Additional information about the Company is available at www.neuralbase.ai or by visiting www.sec.gov.
About NEURALBASE AI LTD.
NeuralBase AI Ltd. (OTC: NBBI) is an AI company developing secure, scalable, and context-aware conversational agents and workflow automation systems. Through its BMP AI platform, now in beta testing, the company enables organizations to streamline internal operations - enhance team collaboration - and increase productivity while maintaining strict compliance and data integrity.
Legal Disclaimer and Forward-Looking Statements
This press release contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, projections, and assumptions made by NeuralBase AI Ltd. (the 'Company' or 'NBBI') in light of experience, current conditions, anticipated future developments, and other factors. Forward-looking statements may include words such as 'aims,' 'anticipates,' 'believes,' 'plans,' 'expects,' 'intends,' 'will,' 'may,' 'could,' 'should,' and similar expressions.
These statements relate to, among other things, the expected performance and capabilities of the BMP AI platform; the Company's ability to successfully complete product development, enter commercial deployment, or scale its technology; future revenues and market expansion; and general strategic direction. All such statements are inherently uncertain and involve a number of risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statement.
NeuralBase AI Ltd. is a fully reporting company with the U.S. Securities and Exchange Commission (SEC) and files annual and quarterly reports, current reports, and other required disclosures. All public filings and disclosures may be reviewed at the SEC's EDGAR database at www.sec.gov. The Company trades on the OTC Markets under the ticker symbol NBBI.
This press release is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of NeuralBase AI Ltd. in the United States or in any other jurisdiction. Offers and sales of securities, if any, will be made only pursuant to an effective registration statement or valid exemption under the U.S. Securities Act of 1933, as amended.
Investing in securities traded on the OTC Markets involves significant risk, including potential loss of principal, low liquidity, high volatility, and limited publicly available information. Shares traded on the OTC Markets may be more susceptible to market manipulation or price swings. Investors are strongly advised to conduct their own due diligence, consult a qualified investment advisor, and carefully review all SEC filings prior to making any investment decision.
Media Contact:
Vighnesh Dobale
Chief Executive Officer
[email protected]
(727) 314-3717
View the original release on www.newmediawire.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market
Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

Business Upturn

time3 hours ago

  • Business Upturn

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth. Regen sees substantial potential in treating chemotherapy-induced bone marrow suppression, a market projected to be valued at well in excess of $1 billion annually. HemaXellerate is designed to stimulate bone marrow regeneration following injury caused by autoimmune conditions, chemotherapy, or radiation. Advertisement HemaXellerate is comprised of cells extracted from the patient's own fat tissue and processed using a proprietary method to induce a biological response in the patient that heals damaged bone marrow and restores the body's ability to generate healthy blood cells. 'Aplastic anemia patients without access to bone marrow transplantation face limited options,' said Dr. David Koos, Chairman and CEO of Regen BioPharma. 'With FDA clearance to begin clinical trials, HemaXellerate has the potential to redefine the treatment landscape—not just for aplastic anemia but for a wide range of hematological disorders. This is a pivotal moment for our company as we work to deliver life-changing therapies to patients worldwide.' To ensure the trial's success, Regen BioPharma has partnered with a clinical research organization (CRO) known for its expertise in conducting complex trials. Once initiated, the study is expected to reach completion within 12 to 14 months. Opportunity: Aplastic anemia is a rare disease with high unmet medical need, offering the potential for accelerated regulatory pathways and market exclusivity. Massive Market Potential: Expansion into chemotherapy-induced bone marrow suppression could unlock a multi-billion-dollar market. Strategic Execution: Collaboration with a leading CRO ensures focused execution and timeline adherence. About Regen BioPharma, Inc. Regen BioPharma, Inc. is a publicly traded biotechnology company (OTC ID: RGBP) and (OTC ID: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject to include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION: Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-722-5505 Phone Email: [email protected] or [email protected] X (formerly twitter): Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Ord Minnett Remains a Sell on Westpac Banking (WEBNF)
Ord Minnett Remains a Sell on Westpac Banking (WEBNF)

Business Insider

time9 hours ago

  • Business Insider

Ord Minnett Remains a Sell on Westpac Banking (WEBNF)

In a report released today, from Ord Minnett maintained a Sell rating on Westpac Banking, with a price target of A$30.00. The company's shares closed yesterday at $23.00. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Ord Minnett, Westpac Banking also received a Sell from Morgans's Nathan Lead in a report issued today. However, yesterday, UBS maintained a Buy rating on Westpac Banking (Other OTC: WEBNF). The company has a one-year high of $23.28 and a one-year low of $16.30. Currently, Westpac Banking has an average volume of 3,277. Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WEBNF in relation to earlier this year.

Morgan Stanley Reaffirms Their Buy Rating on Telstra Corporation Limited (TTRAF)
Morgan Stanley Reaffirms Their Buy Rating on Telstra Corporation Limited (TTRAF)

Business Insider

time9 hours ago

  • Business Insider

Morgan Stanley Reaffirms Their Buy Rating on Telstra Corporation Limited (TTRAF)

In a report released today, Andrew McLeod from Morgan Stanley maintained a Buy rating on Telstra Corporation Limited, with a price target of A$4.95. The company's shares closed last Friday at $3.35. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, McLeod is a 3-star analyst with an average return of 3.3% and a 55.56% success rate. McLeod covers the Communication Services sector, focusing on stocks such as Telstra Corporation Limited, CAR Group, and Event Hospitality & Entertainment Ltd.. In addition to Morgan Stanley, Telstra Corporation Limited also received a Buy from Jefferies's Roger Samuel in a report issued on August 1. However, today, Bell Potter maintained a Hold rating on Telstra Corporation Limited (Other OTC: TTRAF). Based on Telstra Corporation Limited's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $11.6 billion and a net profit of $1.03 billion. In comparison, last year the company earned a revenue of $11.43 billion and had a net profit of $964 million

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store